Compare Biogen Inc (BIIB) vs Global X Copper Miners ETF (COPX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Global X Copper Miners ETF — how do they compare? Biogen Inc trades at $204.94 (market cap $30.13B), while Global X Copper Miners ETF trades at $89.36. Which is the better fit depends on your goals.
| BIIB | COPX | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $95.70 |
52-Week Low | $128.93 | $46.08 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
COPX, the Global X Copper Miners ETF, trades at $89.43, down slightly by 0.09% today. The technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels indicating overbought conditions. Recent news highlights institutional accumulation, with 180 Wealth Advisors increasing its stake by 28.1% in Q2 2026 (SEC filing, August 6, 2026). The ETF is positioned to benefit from copper demand driven by AI infrastructure and electrification trends.
The investment case for COPX hinges on structural copper demand growth from AI data centers and green energy, though it faces risks from commodity price volatility and mining supply constraints. Analysts view the recent pullback as a buying opportunity, citing operational leverage to copper prices. Key risks include cyclical mining downturns and execution challenges among constituent companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →
